Core Viewpoint - The company, HeFu China, has completed its investigation into abnormal stock trading and will resume trading on November 20, 2025, after a significant stock price increase of 256.29% over fourteen trading days, despite the company being in a loss position [1][4][5]. Financial Performance - For the third quarter of 2025, HeFu China reported a net profit attributable to shareholders of -5.048 million yuan, a decline of 225.26% year-on-year [7]. - The company's revenue for the third quarter was 548.862 million yuan, down 22.80% compared to the same period last year [7]. - The latest price-to-earnings (P/E) ratio stands at 343.67, significantly higher than that of industry peers, indicating a potential bubble in stock price [5][6]. Stock Trading Activity - HeFu China's stock experienced a remarkable increase, with twelve out of fourteen trading days closing at the daily limit, reflecting a speculative trading environment [5][6]. - The stock's trading volume showed significant fluctuations, suggesting a "hot potato" effect among investors [6]. Company Overview - HeFu China, established in 2000 and headquartered in Shanghai, is the only medical enterprise listed on both the A-share market and the Taiwan Securities Over-the-Counter Market [6]. - The company primarily provides procurement and logistics services for in vitro diagnostic products, which account for over 90% of its total revenue [6].